RxDoctor Payments Data

Ayham Aboeed, MD

Critical Care Medicine · Bakersfield, CANPI 1093969750

Payments from drug & device makers

$3,967in general payments, 2019–2025

Across 120 payments — averaging $33.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$2K
  • Astellas Pharma US Inc$821
  • Pfizer$281
  • E.r. Squibb & Sons, L.L.C.$215
  • Regeneron Healthcare Solutions, Inc.$188
  • Boehringer Ingelheim$146
  • plus $651 from 16 others

What the payments were for

  • Travel & lodging$1,66542%
  • Food & beverage$1,87447%
  • Education$42911%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,967 in reported general payments places this provider in the 80th percentile of 715 critical care medicine providers in California.

See all critical care medicine providers in California

Medicare billing

Part B allowed, 2024
$40,763
Medicare patients
153
Services billed
398

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CresembaIsavuconazonium Sulfate12$73,213
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$19,207
Breo ElliptaFluticasone/Vilanterol21$8,083
Fluticasone-VilanterolFluticasone/Vilanterol13$4,381
Arnuity ElliptaFluticasone Furoate11$2,333
Albuterol Sulfate HfaAlbuterol Sulfate37$1,480
Ventolin HfaAlbuterol Sulfate13$687
Fluticasone Propionate38$257
Montelukast Sodium24$201

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncCresemba$821$73,21312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 715 critical care medicine providers in California.

Other critical care medicine in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →